Department of Population Health Sciences, University of Utah, Salt Lake City, UT (A.B.P.).
Department of Epidemiology (L.D.C., J.N.B., E.B.L. P.M.), University of Alabama at Birmingham, Birmingham, AL.
Circulation. 2019 Jan 2;139(1):24-36. doi: 10.1161/CIRCULATIONAHA.118.035640.
Over 10 years, achieving and maintaining 2017 ACC/AHA guideline goals could prevent 3.0 million (UR, 1.1-5.1 million), 0.5 million (UR, 0.2-0.7 million), and 1.4 million (UR, 0.6-2.0 million) cardiovascular disease (CVD) events compared with maintaining current blood pressure (BP) levels, achieving 2003 Seventh Joint National Committee Report goals, and achieving 2014 Eighth Joint National Committee goals, respectively. We estimated the number of cardiovascular disease events prevented and treatment-related serious adverse events incurred over 10 years among US adults with hypertension by achieving 2017 ACC/AHA guideline-recommended BP goals compared with (1) current BP levels, (2) achieving 2003 Seventh Joint National Committee Report BP goals, and (3) achieving 2014 Eighth Joint National Committee panel member report BP goals.
US adults aged ≥45 years with an indication for BP treatment were grouped according to recommendations for antihypertensive drug therapy in the 2017 ACC/AHA guideline, 2003 Seventh Joint National Committee Report, and 2014 Eighth Joint National Committee. Population sizes were estimated from the 2011 to 2014 National Health and Nutrition Examination Surveys. Rates for fatal and nonfatal CVD events (stroke, coronary heart disease, or heart failure) were estimated from the REGARDS (REasons for Geographic And Racial Differences in Stroke) study, weighted to the US population. CVD risk reductions with treatment to BP goals and risk for serious adverse events were obtained from meta-analyses of BP-lowering trials. CVD events prevented and treatment-related nonfatal serious adverse events over 10 years were calculated. Uncertainty surrounding main data inputs was expressed in uncertainty ranges (UR).
Over ten years, achieving and maintaining 2017 ACC/AHA guideline goals compared with current BP levels, achieving 2003 Seventh Joint National Committee Report goals, or achieving 2014 Eighth Joint National Committee goals could prevent 3.0 million (UR, 1.1-5.1 million), 0.5 million (UR, 0.2-0.7 million), or 1.4 million (UR, 0.6-2.0 million) CVD events, respectively. Compared with current BP levels, achieving and maintaining 2017 goals could prevent 71.9 (UR, 26.6-122.3) CVD events per 1000 treated. Achieving 2017 guideline BP goals compared with current BP levels could also lead to nearly 3.3 million more serious adverse events over 10 years (UR, 2.2-4.4 million).
Achieving and maintaining 2017 ACC/AHA BP goals could prevent a greater number of CVD events than achieving 2003 Seventh Joint National Committee Report or 2014 Eighth Joint National Committee BP goals but could also lead to more serious adverse events.
在过去的 10 年中,与维持当前血压水平、实现 2003 年第七次联合国家委员会报告目标以及实现 2014 年第八次联合国家委员会目标相比,实现和维持 2017 ACC/AHA 指南目标可预防 300 万(UR,110-510 万)、50 万(UR,20-70 万)和 140 万(UR,60-200 万)例心血管疾病(CVD)事件。我们估计,与维持当前血压水平、实现 2003 年第七次联合国家委员会报告目标或实现 2014 年第八次联合国家委员会目标相比,2017 ACC/AHA 指南推荐的血压目标可预防美国高血压成年患者在 10 年内发生心血管疾病事件,并降低与治疗相关的严重不良事件发生率。
根据 2017 ACC/AHA 指南、2003 年第七次联合国家委员会报告和 2014 年第八次联合国家委员会小组报告中推荐的抗高血压药物治疗建议,将年龄≥45 岁且有血压治疗指征的美国成年人分组。根据 2011 年至 2014 年全国健康与营养调查的数据估计人口规模。从 REGARDS(地理和种族差异中风原因)研究中估计致命和非致命 CVD 事件(中风、冠心病或心力衰竭)的发生率,并根据美国人口进行加权。从降压试验的荟萃分析中获得治疗至血压目标的 CVD 风险降低率和严重不良事件风险。计算 10 年内预防的 CVD 事件和与治疗相关的非致命性严重不良事件。主要数据输入的不确定性用不确定性范围(UR)表示。
与当前血压水平相比,在过去 10 年中,实现和维持 2017 ACC/AHA 指南目标、实现 2003 年第七次联合国家委员会报告目标或实现 2014 年第八次联合国家委员会目标,可分别预防 300 万(UR,110-510 万)、50 万(UR,20-70 万)或 140 万(UR,60-200 万)例 CVD 事件。与当前血压水平相比,实现和维持 2017 年目标可预防每 1000 例治疗患者中 71.9 例(UR,26.6-122.3)CVD 事件。与当前血压水平相比,实现 2017 年指南血压目标也可能导致 10 年内严重不良事件增加近 330 万例(UR,220-440 万例)。
与实现 2003 年第七次联合国家委员会报告或 2014 年第八次联合国家委员会血压目标相比,实现和维持 2017 ACC/AHA 血压目标可预防更多的 CVD 事件,但也可能导致更多的严重不良事件。